Ali Fatehi Hassanabad1, Rania Chehade2, Daniel Breadner3, Jacques Raphael3. 1. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. ali.fatehihassanabad@ahs.ca. 2. Department of Medicine, Schulich School of Medicine and Dentistry, Schulich School of Medicine and Dentistry at Western University, London, ON, Canada. 3. Department of Oncology, Division of Medical Oncology, London Regional Cancer Program, Schulich School of Medicine and Dentistry at Western University, London, ON, Canada.
Abstract
BACKGROUND: Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC. CONCLUSIONS: Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EAC patients that will benefit from selective targeted therapies and/or combinations thereof.
BACKGROUND:Patients with esophageal cancer are confronted with high mortality rates. Whether it is esophageal squamous cell carcinoma (ESCC) or esophageal adenocarcinoma (EAC), patients usually present at advanced stages, with treatment options traditionally involving chemotherapy in metastatic settings. With the comprehensive genomic characterization of esophageal cancers, targeted therapies are gaining interest and agents such as ramucirumab, trastuzumab and pembrolizumab are already being used for the treatment of EAC. CONCLUSIONS: Pembrolizumab has recently been FDA-approved for PD-L1 positive, locally advanced or metastatic ESCC. Despite comprehensive molecular characterization, however, available targed therapies for ESCC are still lagging behind. Herein, we discuss current trends towards more targeted therapies in esophageal cancers, taking into consideration unique features of ESCCs and EACs. Patients progressing on standard therapies should be subjected to genomic profiling and considered for clinical trials aimed at testing targeted therapies. Future targeted therapies may include CDK4/6 inhibitors, PARP inhibitors and inhibitors targeting the NRF2 and Wnt signaling pathways. Ultimately, optimized biomarker assays and next generation sequencing platforms may allow for the identification of subcategories of ESCC and EACpatients that will benefit from selective targeted therapies and/or combinations thereof.
Authors: Peter C Thuss-Patience; Manish A Shah; Atsushi Ohtsu; Eric Van Cutsem; Jaffer A Ajani; Hugo Castro; Wasat Mansoor; Hyun Cheol Chung; Gyorgy Bodoky; Kohei Shitara; Gail D Lewis Phillips; Tina van der Horst; Marie-Laurence Harle-Yge; Betsy L Althaus; Yoon-Koo Kang Journal: Lancet Oncol Date: 2017-03-23 Impact factor: 41.316
Authors: J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Yung-Jue Bang; Jae Yong Cho; Yeul Hong Kim; Jin Won Kim; Maria Di Bartolomeo; Jaffer A Ajani; Kensei Yamaguchi; Agnes Balogh; Teresa Sanchez; Markus Moehler Journal: Clin Cancer Res Date: 2017-06-27 Impact factor: 12.531
Authors: C Luchini; F Bibeau; M J L Ligtenberg; N Singh; A Nottegar; T Bosse; R Miller; N Riaz; J-Y Douillard; F Andre; A Scarpa Journal: Ann Oncol Date: 2019-08-01 Impact factor: 32.976
Authors: Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass Journal: Nat Genet Date: 2013-03-24 Impact factor: 38.330
Authors: James Y Dai; Xiaoyu Wang; Matthew F Buas; Chengjuan Zhang; Jie Ma; Bing Wei; Yin Li; Baosheng Zhao; Teresa S Hyun; Xueyan Chen; Keith R Loeb; Robert Odze; Lena Yao; Xin Sun; Steve Self; Thomas L Vaughan; Yongjun Guo Journal: Commun Biol Date: 2018-10-24